Skip to main content
. 2015 Sep 1;8(9):10130–10138.

Figure 2.

Figure 2

High SOX9 expression correlates with poor patient survival in multiple cancer datasets. Kaplan-Meier curves showing the overall survival analysis in patients with high and low expressions of SOX9 from nine public tumor datasets. A: Glioblastoma dataset (GSE7696: high expression, n = 40; low expression, n = 40; P = 0.0104, log-rank analysis). B: Glioblastoma dataset (GSE42669; high expression, n = 27; low expression, n = 28; P = 0.0291, log-rank analysis). C: Low-grade glioma TCGA dataset (high expression, n = 55; low expression, n = 55; P = 0.0382, log-rank analysis). D: Medulloblastoma dataset (GSE28245; high expression, n = 32; low expression, n = 32; P = 0.0029, log-rank analysis). E: Ovarian cancer (Ovarian Ca) dataset (GSE13876; high expression, n = 208; low expression, n = 207; P = 0.0009, log-rank analysis). F: Lymphoma dataset (GSE10846; high expression, n = 207; low expression, n = 207; P = 8.434e-06, log-rank analysis). G: TCGA head and neck squamous cell carcinoma (HNSCC) dataset (high expression, n = 142; low expression, n = 141; P = 0.0404, log-rank analysis). H: MSKCC prostate cancer dataset (high expression, n = 70; low expression, n = 70; P = 0.0133, log-rank analysis). I: Lung cancer (LuCa) dataset (GSE11117; high expression, n = 21; low expression, n = 20; P = 0.0067, log-rank analysis).